174 related articles for article (PubMed ID: 38719507)
1. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
2. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
[TBL] [Abstract][Full Text] [Related]
3. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
[TBL] [Abstract][Full Text] [Related]
4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
5. Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.
Yan C; Thijs L; Cao Y; Trenson S; Zhang ZY; Janssens S; Staessen JA; Feng YM
Hypertension; 2020 Aug; 76(2):420-431. PubMed ID: 32639887
[TBL] [Abstract][Full Text] [Related]
6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
7. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
[TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
12. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
[TBL] [Abstract][Full Text] [Related]
13. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
14. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
Libianto R; Davis TM; Ekinci EI
Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
[TBL] [Abstract][Full Text] [Related]
15. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
[TBL] [Abstract][Full Text] [Related]
16. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
17. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
19. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
[TBL] [Abstract][Full Text] [Related]
20. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]